A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

NCT07208773 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

260

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Non Small Cell Lung Cancer
Small Cell Lung Cancer

Interventions

DRUG: YL201
DRUG: Ivonescimab

Sponsor

MediLink Therapeutics (Suzhou) Co., Ltd.

Collaborators

[object Object]